Vanberra Signal
Kentaa Care logo

Kentaa Care

Curated by Signal

Equity-based crowdfunding platform supporting healthcare institutions with fundraising.

Overview

Kentaa Care operates in the equity-based crowdfunding sector, focusing on online fundraising solutions for healthcare institutions. The company enables these organizations to raise capital through crowdfunding, event fundraising, and community mobilization, addressing the challenge of obtaining funding beyond traditional subsidies. The platform includes tools for campaign management, such as investment processing and shareholder communication, and offers detailed company profiles and market analyses to assist in decision-making. Kentaa Care targets care institutions and operates on a no-cure-no-pay basis, meaning clients incur costs only when fundraising efforts are successful. The platform also provides educational resources, including webinars, to enhance user knowledge and support the financial needs of the healthcare sector.

Key facts

Founded
2019
Tags

Business model

Contact

More on Vanberra Signal

Members only

Competitors & similar companies

More Crowdfunding companies
  • Equity crowdfunding platform promoting alcohol-free fundraising for cancer support.

    CrowdfundingToronto, Canada
  • Equity crowdfunding platform investing in impactful science and frontier-tech.

    CrowdfundingSan Francisco, United States
  • Online crowdfunding platform for projects

    CrowdfundingDublin, Ireland
+ 234 more similar companies on Signal

About Kentaa Care

What does Kentaa Care do?

Kentaa Care operates in the equity-based crowdfunding sector, focusing on online fundraising solutions for healthcare institutions.

Where is Kentaa Care headquartered?

Kentaa Care is headquartered in Arnhem, Netherlands.

When was Kentaa Care founded?

Kentaa Care was founded in 2019.

Which sector is Kentaa Care in?

Kentaa Care operates in Crowdfunding, part of Financial Technology.

Who are Kentaa Care's competitors?

Companies similar to Kentaa Care include Dry Feb, Sciencevest, and IFINX.